3 ways to prevent head and neck cancer
Katharine Price, M.D., a medical oncologist with the Mayo Clinic Comprehensive Cancer Center in Rochester, says there are three ways to reduce your risks and help prevent head and neck cancer.
Tobacco and alcohol use increase the risk of non-HPV tumors, while HPV is responsible for about 70% of head and neck cancers.
"What's important about that is they have different biology and are much more treatable, meaning they respond better to treatments and tend to have a higher cure rate. We're sort of treating those differently than how we treat some of the non-HPV cancers," Dr. Price says.
Surgery, radiation and chemotherapy are all treatment options, but Dr. Price says it is better to reduce the risks of infection.
"The big three: no smoking tobacco use, minimizing alcohol and then HPV vaccination," she says.
"We know that smoking and alcohol are big risk factors for head and neck cancer if you do both. This increases your risk even more," Dr. Price says.
And she encourages eating a healthy diet.
"We really should be striving to have a good whole-food diet, trying to minimize eating processed foods and refined sugars," Dr. Price says.
About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion, expertise and answers to everyone who needs healing. Visit the Mayo Clinic News Network for additional Mayo Clinic news.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Web Release
5 days ago
- Web Release
Mayo Clinic researchers validate blood test to diagnose Alzheimer's disease in outpatient memory clinics
Alzheimer's disease, marked by memory loss, trouble concentrating and thinking, and changes in personality and behavior, devastates patients, their families and loved ones. With new treatments available for people with early signs of Alzheimer's disease, there is a growing need for accessible and cost-effective tests to diagnose the disease sooner. In a new study, Mayo Clinic researchers confirmed the accuracy of an FDA-approved blood test that can be used at outpatient memory clinics to diagnose the disease in patients with a range of cognitive impairment. The findings are published in Alzheimer's and Dementia: The Journal of the Alzheimer's Association. Standard ways of measuring the buildup of toxic proteins in the brain that indicate Alzheimer's disease include positron emission tomography, or PET scans, and spinal taps. But these tests can be expensive and invasive. More accessible, non-invasive and cost-effective biomarkers — measurable indicators of a disease — are needed to improve diagnoses broadly in clinical settings. 'Our study found that blood testing affirmed the diagnosis of Alzheimer's disease with 95% sensitivity and 82% specificity,' says corresponding author Gregg Day, M.D., a Mayo Clinic neurologist, dementia specialist and clinical researcher. 'When performed in the outpatient clinical setting, this is similar to the accuracy of cerebrospinal fluid biomarkers of the disease and is much more convenient and cost-effective.' The research team says their findings show promise in: Better identifying research participants with Alzheimer's disease brain changes. Screening and selecting patients with Alzheimer's disease for clinical trials. Assessing how patients respond to therapy in clinical trials. More than 500 patients receiving treatment for a range of memory issues at the outpatient Memory Disorder Clinic at Mayo Clinic in Florida participated in the study. They included patients with early- and late-onset cognitive impairment, typical and atypical Alzheimer's disease, Lewy body dementia and vascular cognitive impairment. Patients ranged from 32 to 89 years old, with the average age of symptom onset being 66. Alzheimer's disease was determined to be the underlying cause of the symptoms in 56% of the patients. The team also conducted serum tests to measure kidney disease, which can influence plasma biomarker concentrations. Mayo Clinic Laboratories tested for two proteins in blood plasma that are associated with amyloid plaque buildup, the hallmark of Alzheimer's disease: A?42/40 and p-tau217. The researchers found that p-tau217 levels were higher in patients with Alzheimer's disease versus those without the disease. Higher plasma p-tau217 concentrations were also associated with impaired kidney function, which researchers say should be taken into account when performing the blood test. Plasma p-tau217 concentrations were positive in 267 out of 509 patients, including 233 of 246 patients (95%) with cognitive impairment attributed to Alzheimer's disease. The study was featured at the American Academy of Neurology Annual Meeting in April. In a previous study, researchers from the Mayo Clinic Laboratories team showed the utility of these blood tests compared to amyloid PET scans in research participants. Dr. Day says the next steps in this research are to evaluate blood-based testing in more diverse patient populations and people with early Alzheimer's disease who show no cognitive symptoms. The team also wants to evaluate disease-specific factors that may alter biomarker accuracy in clinical trials. Other Mayo Clinic authors include Yoav Piura, M.D., Christian Lachner, M.D., Joshua Bornhorst, Ph.D., Alicia Algeciras Schimnich, Ph.D., and Neill Graff-Radford, M.D. For a full list of authors, funding and disclosures, see the paper.
Web Release
07-08-2025
- Web Release
Study finds long-term health benefits from bariatric surgery and liver transplant
How obesity and liver disease are connected The percentage of liver transplant candidates in the U.S. with obesity continues to climb, with more than 41% of candidates having a body mass index above 30 in 2022. Obesity puts people at risk of developing metabolic dysfunction-associated steatotic liver disease, or MASLD, formerly known as nonalcoholic fatty liver disease. It's a condition where excess fat accumulates in the liver, which can lead to inflammation, scarring and advanced liver disease. Patients with a body mass index of 40 are more likely to be denied a transplant due to their weight. 'Since MASLD is a leading cause of liver failure, it only makes sense to protect the precious, lifegiving new liver from the same damage that led to the patient needing a transplant in the first place. Safely combining the two procedures protects the transplanted liver and can provide profound health benefits to these patients,' says Todd Kellogg, M.D., Mayo Clinic bariatric surgeon and the study's co-author. What about using new prescription medications for weight loss? New weight loss medications, such as GLP-1s, are being used to help some pre-transplant and post-transplant patients manage their weight. Still, Mayo Clinic experts say bariatric surgery remains an important option for patients with severe obesity due to its safety, proven effectiveness and lasting results. Another recent Mayo study related to kidney transplant patients supports this. 'The patients that we're talking about really have a significant amount of extra weight. The issue with the GLP-1 medications is they are effective in terms of weight loss as well as other benefits which are being identified, but they may not get these patients with severe obesity to their lasting goal of a healthier weight,' Dr. Heimbach says.
Zawya
07-08-2025
- Zawya
Study finds long-term health benefits from bariatric surgery and liver transplant
Dubai, United Arab Emirates - Simultaneous bariatric surgery and liver transplant for patients who are severely obese is safe and improves long-term health outcomes, according to a recent Mayo Clinic study. This combined approach offers a needed solution for these patients who are often denied a lifesaving liver transplant due to their weight. The 10-year study, published in the Journal of Hepatology, compared patients who received only a liver transplant with those who underwent both a liver transplant and bariatric surgery. The combined approach resulted in sustained weight loss, reduced risk of type 2 diabetes and lower risk of fatty liver disease recurrence. Importantly, the combined procedure posed no additional risks compared to liver transplant alone. "We've been amazed by the transformation our patients experience," says Julie Heimbach, M.D., director of Mayo Clinic Transplant Center in Minnesota and the study's senior author. "This dual approach prevents long-term obesity complications like diabetes, heart disease and cancer, while also preventing fatty liver disease recurrence." How obesity and liver disease are connected The percentage of liver transplant candidates in the U.S. with obesity continues to climb, with more than 41% of candidates having a body mass index above 30 in 2022. Obesity puts people at risk of developing metabolic dysfunction-associated steatotic liver disease, or MASLD, formerly known as nonalcoholic fatty liver disease. It's a condition where excess fat accumulates in the liver, which can lead to inflammation, scarring and advanced liver disease. Patients with a body mass index of 40 are more likely to be denied a transplant due to their weight. "Since MASLD is a leading cause of liver failure, it only makes sense to protect the precious, lifegiving new liver from the same damage that led to the patient needing a transplant in the first place. Safely combining the two procedures protects the transplanted liver and can provide profound health benefits to these patients," says Todd Kellogg, M.D., Mayo Clinic bariatric surgeon and the study's co-author. What about using new prescription medications for weight loss? New weight loss medications, such as GLP-1s, are being used to help some pre-transplant and post-transplant patients manage their weight. Still, Mayo Clinic experts say bariatric surgery remains an important option for patients with severe obesity due to its safety, proven effectiveness and lasting results. Another recent Mayo study related to kidney transplant patients supports this. "The patients that we're talking about really have a significant amount of extra weight. The issue with the GLP-1 medications is they are effective in terms of weight loss as well as other benefits which are being identified, but they may not get these patients with severe obesity to their lasting goal of a healthier weight," Dr. Heimbach says. Bringing together experts from different medical specialties is essential when treating these patients, says Ty Diwan, M.D., Mayo Clinic transplant surgeon and the study's co-author. "This study shows that caring for these complex patients extends beyond the transplant itself," Dr. Diwan says. "Multidisciplinary care is required to maximize patient outcomes, and that is what we see in this data. By bringing together experts in very different fields, we've improved patient care and overall health outcomes."
